# Biotech Daily Digest — 2026-01-11

**4 items from 1 sources**

## Summary by Source

- Endpoints News: 4 items


## Endpoints News

- **[Biotech's 2026 outlook: Six questions for the year ahead](https://endpoints.news/biotechs-2026-outlook-six-questions-for-the-year-ahead/)**  
  _Sun, 11 Jan 2026 13:45:23 +0000_  
  This feels like a truly pivotal year for the industry, for the markets and for Washington. It’s been one of the biggest periods of change since I started at Endpoints News three-plus years ago. So ...

- **[Mirador raises $250M, with plans to become an immunology powerhouse](https://endpoints.news/mirador-raises-250m-with-plans-to-become-an-immunology-powerhouse/)**  
  _Sun, 11 Jan 2026 13:30:31 +0000_  
  Mirador Therapeutics, which is developing precision medicines for immune diseases, has raised a $250 million series B financing and is considering an IPO later this year, the company told Endpoints News exclusively ...

- **[Genentech CEO says pharmacy benefit manager shift will save $70M](https://endpoints.news/genentech-ceo-says-pharmacy-benefit-manager-shift-will-save-70m/)**  
  _Sun, 11 Jan 2026 13:00:10 +0000_  
  Genentech's shift from one of the largest drug benefit plans to a privately-held entity is expected to save the Roche subsidiary tens of millions of dollars, the company's CEO said.

 Genentech CEO Ashley Magargee exclusively ...

- **[Hair growth biotech Veradermics files for IPO to fund oral Rogaine](https://endpoints.news/hair-growth-biotech-veradermics-files-for-ipo-to-fund-oral-rogaine/)**  
  _Sat, 10 Jan 2026 18:07:44 +0000_  
  Veradermics, a biotech working on an oral version of the hair growth drug Rogaine, has filed for an initial public offering.

 The Connecticut startup unveiled its IPO plans on Friday evening ...
